A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
RecruitingPhase 3
A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.
About the study
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
What is being tested
- AZD6234 (drug)
- Placebo (drug)
Sponsor: AstraZeneca · Participants: 2,500 · Started: Aug 19, 2026
Contact the study team
- AstraZeneca Clinical Study Information Center · Phone: 1-877-240-9479
Official record on ClinicalTrials.gov — NCT07784725
Locations in the U.S.
| Alabama | Research Site, Dothan (Not yet recruiting) Research Site, Huntsville (Not yet recruiting) |
| Arizona | Research Site, Mesa (Not yet recruiting) |
| California | Research Site, Escondido (Not yet recruiting) |
| Florida | Research Site, Clearwater (Not yet recruiting) Research Site, Jacksonville (Not yet recruiting) |
| Georgia | Research Site, Stockbridge (Not yet recruiting) |
| Illinois | Research Site, Champaign (Not yet recruiting) Research Site, Chicago (Not yet recruiting) |
| Iowa | Research Site, Ames (Not yet recruiting) |
| Michigan | Research Site, Troy (Not yet recruiting) |
| Missouri | Research Site, Jefferson City (Not yet recruiting) Research Site, Kansas City (Not yet recruiting) |
| Montana | Research Site, Butte (Not yet recruiting) |
| Nevada | Research Site, Las Vegas (Not yet recruiting) |
| New Jersey | Research Site, Jersey City (Not yet recruiting) |
| New York | Research Site, Cortland (Not yet recruiting) |
| North Carolina | Research Site, Statesville (Not yet recruiting) |
| North Dakota | Research Site, Fargo (Not yet recruiting) |
| Ohio | Research Site, Columbus (Not yet recruiting) |
| Oklahoma | Research Site, Tulsa (Not yet recruiting) |
| Oregon | Research Site, Portland (Not yet recruiting) |
| Pennsylvania | Research Site, Philadelphia (Not yet recruiting) Research Site, Smithfield (Not yet recruiting) |
| Tennessee | Research Site, Kingsport (Not yet recruiting) |
| Texas | Research Site, Houston (Not yet recruiting) Research Site, San Antonio (Not yet recruiting) Research Site, Sugar Land (Not yet recruiting) Research Site, Waco (Not yet recruiting) |
| Utah | Research Site, Salt Lake City (Not yet recruiting) |
| Virginia | Research Site, Arlington (Not yet recruiting) |
| Washington | Research Site, Seattle (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.